SINCE THE INITIAL description of the Ki-1 monoclonal antibody (MoAb) in 1982, 1 there has
been an overwhelming flood of information concerning the Hodgkin's disease (HD) …

CD30 was originally described as a marker of Hodgkin's and Reed–Sternberg cells in
Hodgkin's lymphoma. Cloning and characterization of cDNAs encoding CD30 and its ligand …

Background Two thirds of patients with advanced Hodgkin's disease are cured with current
approaches to treatment. Prediction of the outcome is important to avoid overtreating some …

Abstract In Hodgkin's disease, Hodgkin and Reed-Sternberg cells consistently express the
antigen CD30. We investigated the possible therapeutic role of an immunotoxin prepared by …

Brentuximab vedotin (SGN-35; Adcetris®) is an anti-CD30 antibody conjugated via a
protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E …

CD30 is found on Reed–Sternberg cells of Hodgkin's disease and on a variety of non-
Hodgkin's lymphoma cells and is up-regulated on cells after Epstein–Barr virus, human T …

Soluble cytokine receptors naturally arise from genes encoding membrane-bound receptors
or are direct derivatives of the receptors themselves. There is mounting evidence that …

Background The safety and efficacy of brentuximab vedotin (BV), an antibody-drug
conjugate directed to the CD30 antigen, has been assessed in several trials in patients with …

In 1982 Stein and coworkers identified a new molecule, CD30 (Ki-1), which is expressed by
Reed–Sternberg (RS) cells of Hodgkin's Disease (HD)(1). Although CD30 is not a specific …

Abstract CD137 (ILA/4‐1BB) is a member of the tumor necrosis factor receptor family and
regulates activation, proliferation and programmed cell death in T lymphocytes. Here we …